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ABSTRACT
Adenosine deaminases that act on RNA (ADARs)
convert adenosine to inosine within double-stranded
regions of RNA, resulting in increased transcriptomic
diversity, as well as protection of cellular double-
stranded RNA (dsRNA) from silencing and improper
immune activation. The presence of dsRNA-binding
domains (dsRBDs) in all ADARs suggests these do-
mains are important for substrate recognition; how-
ever, the role of dsRBDs in vivo remains largely un-
known. Herein, our studies indicate the Caenorhabdi-
tis elegans ADAR enzyme, ADR-2, has low affinity for
dsRNA, but interacts with ADR-1, an editing-deficient
member of the ADAR family, which has a 100-fold
higher affinity for dsRNA. ADR-1 uses one dsRBD to
physically interact with ADR-2 and a second dsRBD
to bind to dsRNAs, thereby tethering ADR-2 to sub-
strates. ADR-2 interacts with >1200 transcripts in
vivo, and ADR-1 is required for 80% of these inter-
actions. Our results identify a novel mode of sub-
strate recognition for ADAR enzymes and indicate
that protein–protein interactions can guide substrate
recognition for RNA editors.
INTRODUCTION
Diverse enzymes catalyze modification of nucleotides in
all types of nucleic acids present in the cell. While trans-
fer RNAs (tRNAs) are the most extensively modified
molecules in the cell (1), recent technological developments
have enabled the detection of several types of modifications
in eukaryotic messenger RNAs (mRNAs) (2,3). Adeno-
sine deamination is the most frequent RNA modification
that directly alters genetic information and results in func-
tional consequences on gene expression (4). Deamination
of adenosine (A) results in inosine (I), which has similar
base-pairing properties as guanosine. Due to these differ-
ences in base pairing, A-to-I editing can alter the amino
acid encoded by a codon, modify splice sites and affect the
interaction of the RNAmolecule with itself or other RNAs,
such as microRNAs (5). In addition, A-to-I editing in long
double-stranded regions has been reported to prevent si-
lencing of host RNAs and improper activation of the im-
mune response by self-RNAs (6–8).
Loss of the enzymes responsible for A-to-I editing,
adenosine deaminases that act on RNA (ADARs), results
in lethality in mice and behavioral phenotypes in worm and
flymodel systems (9–13). Consistent with important roles in
normal development and proper neuronal function, alter-
ations in RNA editing occur in over 35 human pathologies,
including several neurological disorders, metabolic diseases
and cancer (14–17). While much effort has focused on iden-
tifying the altered editing that occurs in disease, the molecu-
lar mechanisms that alter ADAR substrate recognition and
RNA editing efficiency in disease are largely unknown (18).
As spatiotemporal editing patterns vary for individual genes
and do not directly correlate with levels of the transcript
or editing enzymes (19,20), specific factors and/or distinct
mechanisms of substrate recognition may be important for
regulating ADAR editing in vivo.
Substrate recognition by ADARs requires the abil-
ity to both bind specific mRNAs and select target
adenosines within the double-stranded region for deam-
ination (21). Biochemical and structural studies indicate
that the deaminase domain interacts with double-stranded
RNA (dsRNA) and contributes to the selection of spe-
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cific adenosines to edit (22–24). However, chimeric stud-
ies between ADARs and other dsRNA-binding proteins
(dsRBPs) indicate that dsRBDs contribute to efficient edit-
ing in vitro (25), and biochemical studies of ADARs show
the dsRBDs are important for providing both high-affinity
binding and selectivity (26–28). While these data suggest
both the dsRBDs and the deaminase domains regulate as-
pects of ADAR substrate recognition in vitro, there is very
little information on how ADAR enzymes select some tar-
gets and discriminate against others in vivo. Early stud-
ies of Xenopus ADAR1 demonstrated that the deaminase
domain was dispensable for ADAR1 binding to nascent
transcripts in vivo, whereas individual deletions of each of
the three dsRBDs resulted in differential transcript local-
ization (29). While these data suggest the dsRBDs present
in ADARs may contribute to in vivo substrate specificity,
dsRBDs can also mediate protein–protein interactions be-
tween ADARs (30,31) and other dsRBPs (31–35). There-
fore, consequences of loss of dsRBDs on in vivo dsRNA
binding by ADARs may be caused by loss of specific tar-
get recognition by the dsRBD or loss of interaction with
important, but yet unidentified co-factors.
To gain insight into the molecular mechanisms of ADAR
substrate recognition, we compared in vitro and in vivo
recognition of dsRNA. We focused on the Caenorhabdi-
tis elegans ADARs as worms lacking A-to-I editing are vi-
able (12), thus providing the opportunity to assess wild-
type (WT) and mutant ADAR proteins in vivo. The C. el-
egans genome encodes two proteins, ADR-1 and ADR-2,
with the common ADAR family domain structure, but pre-
vious studies have shown that ADR-2 is the only active A-
to-I editing enzyme in worms (12,36). Although ADR-1 is
a deaminase-deficient ADAR family member, ADR-1 pro-
motes editing by ADR-2 at specific adenosines across the
transcriptome (36). The ability of ADR-1 to promote edit-
ing byADR-2 is critical for proper neuronal function, as ev-
idenced by our recent finding that both ADR-1 and ADR-
2 are required for proper editing and neural expression of
an mRNA that is needed for proper chemotaxis of worms
(37). To understand the mechanistic function of these two
proteins in A-to-I editing, we developed an expression sys-
tem that enables production ofC. elegansADARproteins in
recombinant forms. By analyzing WT and mutant ADAR
proteins in vitro as well as in vivo, we demonstrate that
ADR-1 and ADR-2 have a direct protein–protein interac-
tion that involves the second dsRBD of ADR-1. In addi-
tion, using an RNA immunoprecipitation (RIP) assay for
ADR-1 and biochemical editing assays, we determined that
ADR-1 primarily binds mRNA through its first dsRBD,
and binds ADR-2 with its second dsRBD, and bothADR-1
dsRBDs are required to promote editing by ADR-2. ADR-
2 RIP coupled to high-throughput sequencing indicated
that ADR-1 was required for ADR-2 to stably associate
with 983 of 1235 transcripts in WT worms. Together, these
findings indicate that ADR-1 acts as an endogenous co-
factor to direct ADR-2 to specific substrates in vivo, and
opens the possibility that ADAR-editing enzymes in hu-
mans could interact with other RNA-binding proteins, in-
cluding deaminase-deficientADAR familymembers, to rec-
ognize different target mRNAs in vivo.
MATERIALS AND METHODS
Strains and culture
Worms were maintained under standard laboratory con-
ditions on Nematode growth media (NGM) plates seeded
with Escherichia coli OP50 (38). Transgenic worm lines
were generated by microinjection into the gonads of young
adult worms of the appropriate genetic background as de-
scribed previously (39). The injection contained the follow-
ing: 1 ng/l of the adr-1 transgene of interest, 20 ng/l
of the dominant marker rab3::gfp::unc-54 (3′ UTR) and
79 ng/l of 1 kb DNA ladder (NEB). Transgenic strains
were maintained by passaging worms expressing the Green
Fluorescent Protein (GFP) marker. As described previously
(39), the transgenes expressing adr-1 were injected with a
modified pBluescript SK plasmid that contained the ge-
nomic adr-1 locus, including the adr-1 promoter (1245 nt
upstream of the start codon) and 3′ UTR (1560 nt down-
streamof the stop codon) and three copies of the FLAGepi-
tope (DYKDHD) immediately after the start codon.Muta-
tions to the dsRBDs of adr-1were generated by polymerase
chain reaction (PCR) and confirmed by Sanger sequenc-
ing. The following transgenic worm strains were utilized
in this study and previously published: BB21 adr-1(tm668)
+ blmEx1[3XFLAG-adr-1 genomic, rab3::gfp::unc-54 (3′
UTR)] (39) and BB21 adr-1(tm668) + blmEx2[3X FLAG-
adr-1 genomic with dsRBD1 (K223E, K224A and K227A)
and dsRBD2 (K583E, K584A and K587A), rab3::gfp::unc-
54 (3′ UTR)] (36). Newly generated transgenic lines include
BB21 adr-1(tm668) + blmEx11[3XFLAG-adr-1 genomic
with mutations in dsRBD1 (K223E, K224A, and K227A),
rab3::gfp::unc-54 (3′ UTR)] and BB21 adr-1(tm668)
+ blmEx12[3X FLAG-adr-1 genomic with mutations in
dsRBD2 (K583E, K584A and K587A), rab3::gfp::unc-54
(3′ UTR)].
Sf9 and Hi5 insect cell cultures were maintained as de-
scribed in the Invitrogen instructionmanual, ‘Guide to Bac-
ulovirus Expression Vector Systems (BEVS) and Insect Cell
Culture Techniques’ and (40), respectively.
RNA immunoprecipitation (RIP) assay
RIP assays for ADR-1 and ADR-2 were performed as de-
scribed previously (36,37). Random hexamers (Thermo-
Scientific) or gene-specific primers (listed in Supplemen-
tary Table S5) were used to synthesize complementary
DNA (cDNA) for the FLAG-ADR-1 RIP and ADR-
2 RIP assays, respectively. The RNA used for quan-
titative real-time PCR (qPCR) was DNase-treated and
stored at −80◦C. The qPCR reactions used gene-specific
primers (see Supplementary Table S5 for sequence infor-
mation, amplicon length and location) was performed to
quantify lam-2 (WormBase ID: WBGene00016913), pop-
1 (WormBase ID: WBGene00004077), C35E7.6 (Worm-
Base ID: WBGene00016458) and clec-41 (WormBase ID:
WBGene00007153) cDNA abundance in both total RNA
(input) and immunoprecipitated RNA from the indicated
strains. qPCR reactions were performed on 1/10 of the total
reverse transcription volume for each sample, with two tech-
nical replicates for each qPCR reaction. The total volume of
the qPCR reactionwas 10l, used the SybrFastMasterMix
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(Kapa Biosystems, cat no: KK4602) and was performed on
an Eppendorf Realplex Mastercycler using the PCR pro-
gram (step 1: 95◦C for 3 min, steps 2–4: 95◦C for 10 s, 61◦C
for 15 s, 72◦C for 20 s, repeat steps 2–4 for 40 cycles, step 5:
melting curve). All qPCR quantification for each biologi-
cal replicate included eight wells of the amplicon of interest
(standards), which were 10-fold serial diluted and used to
generate a standard curve of cycle threshold versus the rel-
ative concentration of amplicon. The standard curves were
plotted with a logarithmic scale in regard to concentration
and fit with a linear line. The fit of the lines (R2) ranged
from 0.98 to 1.00, and all data points fell within the stan-
dard curve. All amplicons spanned an exon–exon junction
(see Supplementary Table S5), which would give rise to an
∼150 bp PCR product from cDNA and a larger product if
genomicDNA contaminationwas present in theRNA sam-
ples. Each qPCR reaction was examined for the presence of
a singular peak in the melting curve step.
ADR-2 RIP-Seq
RNA was isolated from input lysates and immunoprecipi-
tates from WT, adr-2(-) and adr-1(-) worms as described
above. Isolated RNA was subjected to ribosomal RNA de-
pletion using Ribo-Zero gold kits (Human/Mouse/Rat: Il-
luminaRef:MRZ116C) according to themanufacturer’s in-
structions (except 1/8 of the recommended Ribo-Zero re-
moval solution was used for IP samples due to the low
amount of RNA present). The rRNA-depleted samples
were used as the starting material to generate sequencing
libraries using the KAPA stranded RNA-seq library prepa-
ration Kit (Illumina Ref: KK8400). Briefly, RNA samples
were fragmented into 200–300 bp strands by high temper-
ature (94◦C for 6 min) and used to make first and second
strands of cDNA. Adapters (KAPA S1 adapter kit Ref:
08005770001) were ligated to the cDNA and the libraries
were amplified using minimal PCR cycles. Libraries were
sequenced on an Illumina NextSeq500 instrument at the
Indiana University Center for Genomics and Bioinformat-
ics. Approximately 30–50 million 75 bp single-end sequence
reads were obtained for each library.
Bioinformatic analysis of RIP reads
In brief, 75 bp single-end, reversely stranded, RNA-
Seq reads were trimmed of adapters and aligned to
ce11(WS262) using the following STAR (v2.5.2b) parame-
ters: [outFilterMultimapNmax 1, outFilterScoreMinOverL-
read 0.66, outFilterMatchNminOverLread 0.66, outFilter-
MismatchNmax 10, outFilterMismatchNoverLmax 0.3].
FeatureCounts (v1.5.2) was used to count mapped reads
to Wormbase (WS262) gene annotations using the [-s 2]
flag for reversely stranded reads. Genes with read counts
of zero across all samples were removed as indicating non-
expressed transcripts. To determine enrichment of tran-
scripts in the IP, RNA-sequencing datasets for two biolog-
ical replicates of both immunoprecipitate and input sam-
ples for each strain were analyzed. Raw read counts were
input into DESeq2 (v1.18.1) to test for ratio of ratios, in
this case ((IPA/InputA)/(IPB/InputB)), using a likelihood
ratio test. To determine high confidence editing sites in the
input RNA-Seq datasets from WT, adr-2(-) and adr-1(-
), the aligned reads for the two replicates of each sam-
ple were merged to increase coverage at edited sites. These
sites were then identified using SAILOR as previously de-
scribed (37). Sites with a confidence of ≥0.99 were called
as high confidence for downstream analysis. Annotation of
these sites was carried out with a custom python script us-
ing the wormbaseWS262 annotations. Transcripts that had
a significant difference in DESeq2 values (Padj < 0.05, us-
ing Benjamini–Hochberg correction) between experimental
(WT or adr-1(-)) and control (adr-2(-)) were considered to
be enriched in the ADR-2 IPs. A list of C. elegans edited
transcripts from several published RNA-seq datasets (37)
was overlapped with the enriched transcripts to determine
the proportion of mRNAs that have been previously iden-
tified as edited.
Construction of baculovirus vectors for expression of ADR-1
and ADR-2
The coding region of adr-1 (WormBase ID: WP: CE32459)
was PCR amplified and cloned into the pFastBacHTB
vector downstream of a 6-histidine tag and a TEV pro-
tease recognition site. Mutations to the individual dsRBDs
of ADR-1 were generated using site-directed mutagene-
sis (KKxxK into EAxxA) and the double dsRBD mutant
was generated by subcloning the dsRBD2 mutations into
the dsRBD1 mutant plasmid. The coding region of adr-
2 (WormBase ID: WP: CE25120) was PCR amplified and
cloned into the pLK2-10His-3C vector (41) immediately
downstream of a 10-histidine tagged maltose-binding pro-
tein (MBP) and a human rhinovirus 3C protease site.Muta-
tions to the dsRBD (KKxxK into EAxxA) of ADR-2 were
generated using site-directed mutagenesis.
Virus production and protein expression
Recombinant baculoviruses expressing ADR proteins were
generated using methods described in the Invitrogen in-
struction manual, ‘Guide to Baculovirus Expression Vector
Systems (BEVS) and Insect Cell Culture Techniques’ as well
as the methods described in (40), respectively. Optimization
of ADR-2 expression was carried out using Titer estimation
for quality control (TEQC) method as described in (42).
Protein purification and quantification
WTADR-1 and ADR-1 dsRBDmutants were expressed in
Sf9 cells. Baculovirus-infected cells were collected by cen-
trifugation 72 h after infection. Cells were resuspended in
Lysis Buffer (20 mM Tris–HCl [pH 8.0], 500 mM NaCl, 5
mM imidazole, 10% glycerol, 1% Triton-X-100) and soni-
cated for 20 s at an amplitude 20 for three times, resting on
ice for 1 min between each sonication (Misonix-ultrasonic
liquid processor). Following ultracentrifugation at 179,200
g for 30 min at 4◦C, the supernatant was added to Ni-NTA
(Qiagen) resin and incubated for 1 h. Resin was washedwith
buffer (20 mM Tris–HCl [pH 8.0], 500 mM NaCl, 35 mM
imidazole, 10% glycerol, 1% Triton-X-100) andHis-ADR-1
was eluted with buffer (20 mM Tris–HCl [pH 8.0], 500 mM
NaCl, 500 mM imidazole, 10% glycerol, 1% Triton-X-100).
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WT ADR-2 and ADR-2 mutants were expressed in Hi5
cells. Baculovirus-infected cells were collected by centrifu-
gation 72 h after infection. Cells were resuspended in Amy-
lose wash buffer (20 mM Tris–HCl [pH 8.0], 500 mM
NaCl, 10%glycerol, 0.1%Triton-X-100), sonicated and cen-
trifuged as described for recombinant ADR-1. The super-
natant was incubated with Amylose resin (NEB) for 1 h
and then washed with 5–10 column volumes of wash buffer.
ADR-2 was cleaved from the amylose-bound MBP tag by
3C protease. Cleaved ADR-2 was diluted and then incu-
bated with Heparin resin (GE Healthcare) and eluted us-
ing a high-salt buffer (20 mM Tris–HCl [pH 8.0], 500 mM
NaCl, 10% glycerol, 0.5 mM 2-Mercaptoethanol).
Both ADR-1 and ADR-2 were dialyzed into stor-
age buffer (20 mM Tris–HCl [pH 8.0], 200 mM KCl,
10% glycerol, 0.5 mM 2-Mercaptoethanol). Protein
purity and concentration were determined by sodium
dodecylsulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Coomassie staining, alongside known
concentrations of bovine serum albumin (BSA-Sigma)
standards. Proteins were concentrated using Amicon
Ultra-4 centrifugal filters (30 K), aliquoted and stored at
−80◦C.
Preparation of radioactively labeled dsRNA
The 200 bp long dsRNA was prepared by amplifying re-
gions of the C. elegans lam-2 3′ UTR that contain 25 sites
that undergoA-to-I editing in vivo, 8 of which requireADR-
1 formaximal editing (36). PCR templates corresponding to
the 5′ and 3′ half of the double-stranded 3′ UTRwere gener-
ated with the forward primer for each template containing a
T7RNApolymerase binding site. PCR templates were indi-
vidually transcribed in the presence of T7RNApolymerase,
Nucleoside triphosphate (NTPs) (100 mMCTP, GTP, UTP
each and 5 mM ATP), and radioactive 32P -ATP. After 2
h, a Chroma-spin column (Clontech) was used to remove
unincorporated nucleotides. RNA concentration was cal-
culated based on the radioactive ATP incorporated in each
strand (measured by a scintillation counter). Equal molar
ratios of each strand were combined and incubated in 1×
annealing buffer (from 5× annealing buffer: 50 mM Tris–
HCl [pH 7.5], 100 mM NaCl, 5 mM ethylenediaminete-
traacetic acid (EDTA)) and then subjected to high heat
(90◦C) for 2 min in a water bath and cooled gradually to
room temperature. The annealed dsRNA was subjected to
Native PAGE at a constant power of 3 W for ∼3 h. The
dsRNAbandwas excised from theNative gel, and theRNA
was allowed to passively diffuse into 350 l of 1× elec-
trophoretic mobility shift assay (EMSA) buffer overnight.
The concentration of the dsRNA was measured using a
Beckman scintillation counter model LS600SC.
The 46 bp long dsRNA was made by annealing two
complementary synthetic ssRNAs from lam-2 3′-UTR re-
gion (Supplementary Table S5). These ssRNAs were end la-
beled with 32P  -ATP using Polynucleotide kinase (Polynu-
cleotide kinase-NEB). Free nucleotides were removed using
microspin columns (Biorad). Annealing of ssRNAs, gel ex-
traction of dsRNA and quantification were performed as
described above.
Gel mobility shift assay
Gel mobility shift assays were performed as previously de-
scribed (26). Briefly, 20 pM dsRNA was incubated with
recombinant proteins in EMSA buffer (50 mM KCl, 10
mM Tris–HCl [pH 8.0], 10% glycerol, 1 mM MgCl2, 0.5
mM dithiothreitol [DTT]) on ice for 30 min. Reactions
were stopped by adding 5× loading buffer (2.5× TBE, 50%
glycerol) and 75% of the reaction was loaded into a Na-
tive 6% (29:1 acrylamide/bisacrylamide (Biorad)) gel. Elec-
trophoresis was performed at 4◦C at 200 V for 2–2.5 h with
0.5× Tris-borate-EDTA (TBE) running buffer. Gels were
dried, exposed to phosphorimager screens overnight and
autoradiographed (Typhoon FLA 9500). ImageQuant TL
(1D v8.1) was used to quantify the bound and free RNA.
RNA-binding isotherms were obtained using GraphPad
Prism 7.0awith a curve fit of specific bindingwithHill slope.
In vitro deamination assay
Worm extracts were made as previously described (12).
Briefly, worms were collected from NGM plates using 1×
M9 buffer (0.04 M Na2HPO4, 0.02 M KH2PO4, 0.009 M
NH4Cl, 0.02 M NaCl) and two volumes of TGKED buffer
(50 mM Tris–HCl [pH 8.0], 50 mM KCl, 150 mM NaCl,
25% glycerol, 0.1 mM EDTA, 0.5 mM DTT) containing
Complete protease inhibitor (Roche) were added to the
worm pellet. The worm suspension was sonicated at an am-
plitude of 20 (power∼4) for 10 s four times and at an ampli-
tude of 35 four times (Misonix-ultrasonic liquid processor),
resting the tube on ice for 1 min between each sonication.
Lysates were centrifuged at 4◦C at 16 000 g for 45 min and
quantified using a Bradford assay. Extracts were aliquoted,
flash frozen and stored at −80◦C.
Deamination reactions (100 l) were performed in as-
say buffer (40 mM Tris–HCl [pH 7.9], 5 mM EDTA, 25
mM KCl, 10 mM NaCl, 1.1 mM MgCl2, 5% glycerol, 1
mM DTT and 0.4 U/l RNasin (Promega)) with a fi-
nal concentration of 1 nM radiolabeled lam-2 3′ UTR
(long) and 100–150 g worm extracts. Reactions were in-
cubated at 20◦C for 2 h and stopped by the addition of
a 10:1 Trizol:chloroform mixture. RNA was isolated from
the aqueous layer, ethanol precipitated and subjected to
cleavage with P1 nuclease (US Biological Life Sciences) at
37◦C for 30 min. Cleaved nucleotides were extracted us-
ing a 25:24:1 phenol/chloroform/isoamyl mixture and then
lyophilized using a speed vacuum. Mononucleotides were
resuspended in water and spotted on a thin-layer chro-
matography (TLC) plate (PEI-cellulose, Selecto Scientific)
that was run with solvent (197.5 ml saturated (NH4)2SO4,
47.5ml 0.1MNaOAc, pH 6.0, 5ml isopropanol) for 2 h, ex-
posed to phosphorimager overnight and autoradiographed
(Typhoon FLA 9500).
Co-IP and pulldown assays
For the in vivo co-IP assay, immunoprecipitates of ADR-
1 with -FLAG magnetic beads were performed as de-
scribed above (RIP assay), except worms were not subjected
to ultraviolet (UV) crosslinking. The immunoprecipitates
were washed with RIP wash buffer, resuspended in 2× SDS
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buffer and subjected to SDS-PAGE. For the in vitro pull-
down assay, Dynabeads (Invitrogen, anti-Rabbit IgG) were
incubated with ADR-2 antibody (PA6496, Fisher Scien-
tific). RIP wash buffer with freshly added detergents (0.1%
NP-40, 0.5% Triton-X-100) was used to wash the antibody-
bound beads before the addition of ADR-2 to the final con-
centration of 5 nM.After 2 h of incubation at 4◦C, unbound
ADR-2 was removed with wash buffer. BSA was added to
the beads at a final concentration of 0.4 g/l to reduce
non-specific binding and incubated for 1 h. The beads were
then incubated with ADR-1 proteins (final concentration
of 3 nM) in EMSA buffer (50 mM KCl, 10 mM Tris–HCl
[pH 8.0], 10% glycerol, 1 mMMgCl2) for 1 h with or with-
out 46 bp dsRNA (0–10 nMfinal concentration). The beads
were washed with RIP wash buffer, resuspended in 30 l of
2× SDS buffer and subjected to SDS-PAGE. Immunoblot-
ting analysis for the in vivo IP utilized FLAG and ADR-2
(PA6496) antibodies, while the in vitro pulldowns utilized
ADR-2 antibody (IU529) and a custom ADR-1 antibody
previously described (39).
RESULTS
ADR-2, the only A-to-I editing enzyme inC. elegans, has a re-
duced affinity for substrate RNAs compared to other ADARs
Deamination of dsRNA by ADARs requires binding of
the editing enzyme to the substrate and base flipping of
the target adenosine (43). To interrogate the biochemical
properties of the C. elegans A-to-I editing enzyme, ADR-
2, we established the first expression and purification pro-
tocol for C. elegans ADR-2 using a BEVS (Supplementary
Figure S1A). Binding of recombinant ADR-2 to dsRNA
was examined using a gel mobility shift assay with a 200
bp dsRNA corresponding to sequence from the 3′ UTR of
lam-2, a known ADR-2 substrate (44). Increasing concen-
trations of ADR-2 (up to 1 M) were incubated with the
200 bp dsRNAand themeasured affinity (Kd,app) was∼76.3
± 2.1 nM (Figure 1A). The shift shows a sharp concentra-
tion dependence similar to cooperative binding, rather than
binding of one ADR-2 molecule (Figure 1B). To rule out
the possibility that the observed shift in dsRNA was a re-
sult of non-specific retardation of dsRNAdue to aggregated
protein molecules, we made mutations in the KKxxKmotif
(Figure 1C) at residues that are critical for dsRNA binding
in other dsRBDs (45–47). Varying concentrations (up to 1
M) of the ADR-2 dsRBD mutant did not result in any
detectable shift of the dsRNA (Figure 1D), indicating that
the observed binding of WT ADR-2 to dsRNA requires a
canonical dsRNA-binding motif.
To date, most ADAR proteins have been shown to bind
tightly to dsRNA, with apparent affinities in the sub-
nanomolar to 10 nM range (48). To test if the relatively
lower affinity of C. elegans ADR-2 was a general property
ofC. elegansADARproteins or a feature unique toADR-2,
C. elegans ADR-1 was expressed in insect cells using BEVS
and purified (Supplementary Figure S1B). Binding of re-
combinant ADR-1 to dsRNA was examined using gel mo-
bility shift assays with the 200 bp dsRNA described above.
Incubation of ADR-1 with the dsRNA resulted in a discrete
shift and complete binding was observed at a low concen-
tration of ADR-1 (titration up to 8 nM) (Figure 1E). The
binding isotherms from three replicate experiments indicate
that ADR-1 binds to dsRNA with a Kd, app= 0.43 ± 0.04
nM (Figure 1G and H). This apparent affinity is over 100-
fold stronger than ADR-2. One notable exception between
ADR-1 and ADR-2 is the presence of two dsRBDs within
ADR-1 and only one dsRBDwithinADR-2 (Figure 1C and
F). To determine if the presence of multiple dsRBDs con-
tributes to the higher affinity ofADR-1 for dsRNA,ADR-1
dsRBD mutants (KKxxK to EAxxA in each dsRBD) were
generated, purified and tested by gel mobility shift assay.
Consistent with previous in vivo binding results (36), an
ADR-1 protein with mutations in both dsRBDs showed no
detectable binding to dsRNA in vitro (Figure 1G and H).
Each of the ADR-1 individual dsRBD mutants bound to
the dsRNA with slightly reduced affinity compared to WT
ADR-1 (Figure 1G and H) (Kd, app= 1.47 ± 0.47 nM for
ADR-1 dsRBD1 mutant and 0.95 ± 0.33 nM for ADR-1
dsRBD2 mutant). However, each ADR-1 dsRBD mutant
still exhibited∼50–80-fold stronger affinity toward dsRNA
than that of ADR-2, which contains a single dsRBD. To-
gether, these data indicate that the dsRBD of C. elegans
ADR-2 has a lower affinity for dsRNA in contrast to all
previously studied ADARs, including C. elegans ADR-1.
ADR-1 binding to mRNAs is not sufficient to regulate editing
in vivo
We have previously shown that ADR-1 promotes editing by
ADR-2 at specific sites across the transcriptome and this
activity requires dsRNA binding by ADR-1 (36). However,
considering the higher in vitro affinity of ADR-1 for dsRNA
(Figure 1) and the fact that ADR-1 is expressed 10-fold
higher than ADR-2 at the mRNA level (39), it is unclear
how ADR-1 would promote editing in vivo and not just
compete with ADR-2 for mRNAs. To begin to address this
question, we examined ADR-1 binding to dsRNA in vivo.
We used an established RIP assay where worms are UV-
irradiated to crosslink bound RNAs before IP of ADR-1
(36). This RIP assay used transgenic worm lines withWT or
mutant ADR-1 with a 3× FLAG epitope at the N-terminus
introduced into an adr-1 null background. These transgenic
worm lines express the genomic sequence of ADR-1 under
the control of the ADR-1 promoter to mimic endogenous
ADR-1 localization and splicing (36). Enrichment of three
known edited mRNAs was measured for WT ADR-1 and
mutants with KKxxK to EAxxAmutations in each or both
dsRBDs and compared to immunoprecipitates from adr-
1(-) worms. Equal expression and IP of WT ADR-1 and
mutants was confirmed by immunoblot (Figure 2A). The
remaining immunoprecipitate portion was treated with pro-
teinaseK to release boundRNAs that were quantified by re-
verse transcription quantitative PCR (RT-qPCR).C35E7.6,
pop-1 and lam-2 were 8–38-fold enriched in the WT ADR-
1 immunoprecipitate compared to the immunoprecipitate
from the adr-1(-) strain (Figure 2B). Furthermore, and con-
sistent with previous data (36), the ADR-1 mutant contain-
ing mutations in both dsRBDs did not show a significant
enrichment for any of the mRNAs when compared to the
immunoprecipitate from the adr-1(-) strain. Interestingly,
and in contrast to the in vitro RNA-binding data, the in-
dividual dsRBD mutants of ADR-1 bound differentially
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Figure 1. ADR-2 exhibits over a 100-fold weaker affinity to dsRNAs than ADR-1. (A) Increasing amounts of WT ADR-2 were mixed with 32P-labeled
200 bp dsRNA from the lam-2 3′UTR (20 pM) and incubated on ice for 30 min. Complex formation was analyzed by native gel electrophoresis. Initial
and final protein concentrations are marked above gel with adjacent lanes representing a 2-fold difference in protein concentration. (B) Autoradiograms
of the dried gels were used to determine the binding affinity of ADR-2 to dsRNA. The average value for % bound at each concentration of protein was
used to generate the binding curve. Error bars indicate standard error mean (SEM) for each point from three replicates of the gel shift. The dissociation
constant (Kd, app) was calculated from the binding curve generated for specific binding using a Hill slope. (C) Schematic of the protein structure for WT
ADR-2 and the ADR-2 dsRBD mutant (ds mut). The dsRBD is shown as an oval (WT in light blue and mutant in white) and the deaminase domain as a
rectangle. The amino acid residues for the lysines within the conserved KKxxK motif are listed above the dsRBD as well as the specific mutations present
in the dsRBDmutant. (D) A representative gel shift assay for the ADR-2 ds mut incubated with 20 pM of the 200 bp lam-2 3′ UTR dsRNA. (E) Increasing
concentrations of WT ADR-1 were mixed with 32P-labeled 200 bp dsRNA corresponding to the sequence from the lam-2 3′-UTR (20 pM). Initial and
final protein concentrations are marked above gel with adjacent lanes representing a 2-fold difference in protein concentration. (F) Schematic of the WT
ADR-1 and ADR-1 dsRBDmutants. (G) RNA-binding isotherms for gel shift assays conducted with the 200 bp RNA and the indicated ADR-1 proteins.
The average value for % bound at each protein concentration was used to generate the binding curve. Error bars indicate SEM for each point from three
replicates of each assay, except ADR-1 ds1+2 mutant where n= 2. (H) Values for the dissociation constant (Kd,app) were calculated from the RNA-binding
isotherms shown in (G).
to mRNAs in vivo (Figure 2B). The ADR-1 dsRBD1 mu-
tant immunoprecipitate had significantly less enrichment
for all three mRNAs compared to WT ADR-1, suggesting
dsRBD1 is essential for ADR-1 to bind mRNAs in vivo. In
contrast, the ADR-1 dsRBD2 mutant immunoprecipitate
had an enrichment similar to WT ADR-1 for all three mR-
NAs, suggesting dsRBD2 does not significantly contribute
to ADR-1 mRNA binding in vivo.
To determine whether ADR-1 binding to mRNA is the
only requirement for ADR-1 to promote editing byADR-2,
the individual ADR-1 dsRBDmutant worms were assessed
in an established biochemical editing assay (12). For this as-
say, extracts were prepared fromadult worms and incubated
with the 200 bp radiolabeled dsRNA corresponding to the
lam-2 3′ UTR. After incubation of the dsRNA with the
worm lysates, the dsRNAwas cleaved into single nucleotide
monophosphates and subjected to TLC, which separates
adenosine (unedited) and inosine (edited) monophosphate.
Extracts were prepared from worms lacking adr-1(-) and
transgenic worms expressing WT ADR-1 and both ADR-
1 individual dsRBD mutants. Equal concentrations of the
lysates were used in the assay and immunoblot indicated
equivalent amounts of the ADR-2-editing enzyme in each
lysate (Supplementary Figure S2A and B). Consistent with
the ability of ADR-1 to promote editing by ADR-2, ex-
tracts from the transgenic FLAG-ADR-1 worms gener-
ate significantly more IMP than the extracts from adr-1(-)
worms (Figure 2C and D). In contrast, the FLAG-ADR-
1 dsRBD1 mutant lysate generated a similar amount of
IMP as the extract from adr-1(-) worms (Figure 2C), in-
dicating that the ability of ADR-1 to bind mRNA in vivo
is essential for the ability of ADR-1 to promote editing
by ADR-2. Surprisingly, the FLAG-ADR-1 dsRBD2 mu-
tant lysate also failed to promote editing by ADR-2 (Figure
2D).As theADR-1 dsRBD2mutantwas capable of binding
mRNA similar to WT (Figure 2B), these data suggest that
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Figure 2. Both dsRBDs of ADR-1 are required to regulate editing in vivo.
(A) Lysates from the indicated worm strains were incubated with -FLAG
magnetic beads. A portion of the lysates before incubation with beads and
the IP were subjected to immunoblotting for the FLAG epitope. (B) Im-
munoprecipitates from (A)were treatedwith proteinaseK to release bound
RNA. RNA was extracted and reverse transcribed. Bar graph represents
the ratio of cDNA in the immunoprecipitates divided by the cDNA in in-
put lysates from the indicated worm strains. Error bars represent SEM
for three biological replicates. A one-way ordinary analysis of variance
(ANOVA) test was performed. Single and double asterisks indicate sig-
nificant changes where P = 0.05 and P ≤ 0.05, respectively, in the RNA
binding between WT ADR-1 and ADR-1 dsRBD mutants. (C and D, left
panels) Phosphorimages of TLC plates with 32P-AMP and 32P-IMPmark-
ers and 32P-AMP-labeled dsRNA digested to mononucleotides after incu-
bation with the indicated lysates or no lysate, as a negative control. (C and
D right panels) AMP and IMP were quantified using image quant and the
% editing was calculated [% Editing = IMPs/ [AMPs + IMPs] and nor-
malized to the amount of editing in the WT FLAG ADR-1 lysate in each
replicate. Student’s t-test was performed on the average value of three in-
dependent replicate experiments for ADR-1 ds1 mutant and two replicate
experiments for ADR-1 ds2 mutant. Average % editing, SEM and the P-
values are shown.
the dsRBD2 of ADR-1 promotes ADR-2 editing through
a function other than RNA binding. Additionally, editing
in the ADR-1 dsRBD1+2 mutant lysate is not significantly
different from the adr-1(-) lysate (Supplementary Figure
S2C–E). Together, these data indicate that both dsRBDs of
ADR-1 are required to regulate editing in vivo.
ADR-1 forms a complex with ADR-2 independent of dsRNA
As the second dsRBD of ADR-1 was required to promote
editing by ADR-2, but not binding of ADR-1 to mRNA in
vivo, we sought to determine whether dsRBD2 of ADR-1
might be required for a direct protein–protein interaction
with ADR-2. In all kingdoms of life, it has been shown
that dsRBPs can interact directly with other dsRBPs via
protein–protein interactions between dsRBDs (49,50). In
particular, studies on human and fly ADARs indicate that
this domain mediates homodimerization between ADARs
and heterodimerization of ADARs with other dsRBPs
(30,31,51). As a first step to determine if dsRBD2 of ADR-
1 mediates a protein–protein interaction with ADR-2, an
in vivo co-IP assay was performed. Briefly, ADR-1 was im-
munoprecipitated using the FLAG epitope present at the
N-terminus of WT or mutant ADR-1. An interaction be-
tweenADR-1 andADR-2 was examined by immunoblot of
the ADR-1 immunoprecipitates with an ADR-2 antibody.
ADR-2 was detected in the immunoprecipitate fromworms
expressing FLAG-ADR-1, but not in the immunoprecipi-
tate from adr-1(-) worms, indicating an in vivo interaction
(Figure 3A). However, it is possible that this interaction is
indirect and mediated by RNA binding. To examine this
possibility, the interaction between ADR-2 and the ADR-
1 mRNA-binding mutant, ADR-1 dsRBD1 EAxxA, was
examined. Interestingly, the ADR-1 dsRBD1 mutant was
capable of pulling down ADR-2, suggesting that dsRNA
binding by ADR-1 is not required for the in vivo interac-
tion of ADR-1 and ADR-2 (Figure 3A). In contrast, IP
of the ADR-1 dsRBD2 mutant and the ADR-1 dsRBD1
+ dsRBD2 mutant resulted in almost no detectable ADR-2
protein in the immunoprecipitate (Figure 3A). Importantly,
immunoblotting for ADR-2 in these lysates indicated that
the absence of ADR-2 in the ADR-1 dsRBD2 mutant and
ADR-1 dsRBD1 + dsRBD2 mutant immunoprecipitates is
not caused by a decrease inADR-2 protein expression in the
mutant lysates compared to theWTADR-1 lysate (Supple-
mentary Figure S3). As the ADR-1 dsRBD2 mutant binds
mRNA similar to WT ADR-1 but is unable to promote
RNA editing by ADR-2, these data suggest that the sec-
ond dsRBD of ADR-1 may be important for mediating a
protein–protein interaction with ADR-2.
To determine if ADR-1 directly interacts with ADR-2,
an in vitro pulldown assay was performed using purified
proteins and a reverse immunoprecipitation order. In this
assay, recombinant ADR-2 was immobilized on magnetic
beads using an ADR-2 antibody and then either recombi-
nant WT ADR-1 or ADR-1 dsRBD mutants were incu-
bated with the ADR-2-bound resin. After stringent wash-
ing, the presence of ADR-1 and ADR-2 on the resin was
determined by immunoblotting. Using this assay, recombi-
nant WT ADR-1 was pulled down by recombinant ADR-
2, but not resin alone (Figure 3B). Consistent with the in
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Figure 3. The second dsRBD of ADR-1 is involved in a protein–protein interaction with ADR-2 that allows for binding of the complex to dsRNA. (A)
Lysates from the indicated worm strains were incubated with -FLAG magnetic beads. The immunoprecipitates were subjected to SDS-PAGE and im-
munoblotting with FLAG (ADR-1) and ADR-2 (PA6496) antibodies (n= 3 independent biological replicates). (B) Magnetic IgG resin was incubated with
antibodies specific for ADR-2 (PA6496). After washing, the resin was divided in half and incubated with buffer or WT recombinant ADR-2 protein for an
hour. After washing, the resins were incubated with the indicated recombinant ADR-1 proteins, washed and subjected to SDS-PAGE and immunoblotting
with ADR-1 and ADR-2 antibodies. Multiple independent replicates were performed for each protein analyzed (n= 5 for ADR-1 ds1 and ADR-1 ds2 mu-
tant, n= 3 for ADR-1 ds1+2 mutant). (C) Similar to the method as described for (B), except for samples were incubated with the indicated concentrations
of a 46 bp dsRNA corresponding to sequence from the lam-2 3′ UTR when the indicated ADR-1 recombinant proteins were added to the magnetic resin
(n = 3 independent replicates). The bound proteins were subjected to SDS-PAGE and immunoblotting with ADR-1 and ADR-2 antibodies. (D) Model
for ADR-1 binding to dsRNA in vitro either alone (top panel) or in complex with ADR-2 (bottom panel). (E and F) Increasing concentrations of ADR-1
and ADR-1+ADR-2 complex were mixed with 32P-labeled 200 bp dsRNA corresponding to the sequence from the lam-2 3′-UTR (20 pM). Initial and
final protein concentrations are marked above gel with adjacent lanes representing a 2-fold difference in protein concentration. The average value for %
bound at each concentration from three replicates was used to generate the binding curves for specific binding with Hill slope. (E) The binding curve of
WT ADR-1 alone (red squares) and ADR-1+ADR-2 complex (orange circles), (F) ADR-1 ds1 mutant alone (dark green circles) and ADR-1 ds1 mutant
in the presence of ADR-2 (green squares), (G) ADR-1 ds2 mutant (dark blue circles) and presence of ADR-2 (blue circles). (E–G) Error bars indicate SEM
for each point from three independent replicates.
vivo co-IP, the ADR-1 dsRBD1mutant was pulled down by
recombinant ADR-2 (Figure 3B). In contrast, the ADR-1
dsRBD2 mutant and the dsRBD1 + dsRBD2 mutants did
not interact with ADR-2 in the pulldown assay (Figure 3B).
These data are consistent with the in vivo co-IP (Figure 3A)
and suggest the second dsRBD of ADR-1 serves as the ma-
jor protein–protein interaction site for ADR-1 and ADR-2.
It is important to note that in both the in vivo and in vitro
co-IP assays, the ADR-1 dsRBD1mutant appears to have a
reduction in binding toADR-2, suggesting that this domain
may partially also contribute to the interaction between
ADR-1 and ADR-2. As dsRBD1 of ADR-1 is the major
contributor of mRNAbinding by ADR-1, it is possible that
RNA binding contributes to the observed interaction be-
tween ADR-1 and ADR-2. As one test of this possibility,
theWT recombinant proteinswere treatedwithmicrococcal
nuclease before performing the in vitro co-IP assay. Impor-
tantly, the ADR-1 and ADR-2 interaction detected in the in
vitro co-IP assay was not altered by treatment of the recom-
binant proteins with micrococcal nuclease (Supplementary
Figure S4), suggesting that RNA is not critical for medi-
ating the interaction between ADR-1 and ADR-2. To fur-
ther probe if dsRNA binding by ADR-1 could contribute
to the observed interaction between ADR-1 and ADR-2,
the in vitro co-IP assay was performed in the presence of
dsRNA with the ADR-1 dsRBD2 mutant, which lacks the
ability to physically interact with ADR-2 but has similar
dsRNAbinding toWTADR-1 (Supplementary Figure S5).
The presence of increasing concentrations of dsRNA did
not affect the interaction of the ADR-1 dsRBD2 mutant
and ADR-2 (Figure 3C), indicating that ADR-1 binding
to dsRNA is not sufficient to mediate the interaction be-
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tween ADR-1 and ADR-2. Interestingly, the presence of
dsRNA (over a range of concentrations, including satura-
tion of both molecules) did not inhibit the interaction of
WT ADR-1 and ADR-2, suggesting that the ADR-1 and
ADR-2 interaction occurs independent of RNA binding.
Together, our in vitro and in vivo data suggest that ADR-
1 and ADR-2 directly interact through ADR-1 dsRBD2,
and ADR-1 dsRBD1 is critical for dsRNA binding in vivo.
As a further test of this model (Figure 3D), gel mobility
shifts were performed with WT and mutant ADR-1/ADR-
2 complexes and the lam-2 200 bp dsRNA, as described
above (Figure 1). Co-incubation of WT ADR-1 and ADR-
2 with the dsRNA resulted in a discrete shift (Supplemen-
tary Figure S6A). Analysis of the binding isotherms from
three replicate experiments indicates that an ADR-1/ADR-
2 complex binds to dsRNA with an approximate Kd, app=
1.50 nM (Figure 3E), which is very similar to the affin-
ity of the individual dsRBD mutants of ADR-1 (Figure 1
and Supplementary Figure S6B). This shift in affinity of
ADR-1 in the presence of ADR-2 is consistent with amodel
that ADR-2 binding to dsRBD2 of ADR-1 forces ADR-
1 to bind dsRNA with dsRBD1 only. To test this hypoth-
esis, the gel shift assays were performed with the ADR-
1 dsRBD mutants in complex with WT ADR-2. As ex-
pected, the presence of ADR-2 did not allow the ADR-
1 dsRBD1 + dsRBD2 mutant to bind dsRNA (data not
shown). ADR-2 significantly reduced dsRNA binding by
ADR-1 dsRBD1 mutant, consistent with this dsRBD be-
ing the primary dsRNA interaction (Figure 3F, P-value =
0.05, unpaired t-test). In contrast, the addition of ADR-
2 did not have any significant change in binding of the
ADR-1 dsRBD2 mutant (Figure 3G). Together these data
suggest that ADR-1 interacts with ADR-2 via the second
dsRBD of ADR-1 and the complex binds dsRNA via the
first dsRBD of ADR-1.
ADR-1 is required for ADR-2 to bind most mRNAs in vivo
While the in vitro dsRNA-binding experiments suggest
ADR-1 is important for the ability of ADR-2 to bind
dsRNA, we sought to determine whether this same require-
ment could be observed in vivo. To examine binding of
ADR-2 to mRNA in vivo, we used an RIP assay for ADR-2
that was recently developed by our laboratory (37). To di-
rectly examine whether the presence of ADR-1 influenced
ADR-2 binding to mRNA, immunoprecipitates from UV-
irradiated WT and adr-1(-) lysates were compared. Im-
portantly, ADR-2 was efficiently immunoprecipitated from
both WT and adr-1(-) lysates, but not from lysates of adr-
2(-) worms (Figure 4A). RT-qPCR showed a 22-fold en-
richment of lam-2 mRNA in the WT immunoprecipitates
compared to the adr-2(-) immunoprecipitates, indicating
that ADR-2 stably associates with the lam-2 mRNA in
WT worms (Figure 4B). However, using adr-1(-) worm
lysates, ADR-2 failed to enrich lam-2, suggesting that, in
vivo, ADR-2 is unable to interact with the lam-2 mRNA in
the absence of ADR-1 (Figure 4B). To test the influence of
ADR-1 on ADR-2 binding to other known targets, we ex-
amined pop-1 and clec-41, two mRNAs in which ADR-1
binding promotes RNA editing (36,37). Pop-1 and clec-41
mRNA were enriched in the ADR-2 immunoprecipitates
from WT worms compared to those from adr-2(-) worms
by 37- and 7-fold, respectively, but both showed dramati-
cally lower enrichment from adr-1(-) worm lysates (Figure
4B). In contrast to the ADR-1 dependence of the ADR-2
interaction with these three mRNAs, the ADR-2 immuno-
precipitates from both WT and adr-1(-) lysates exhibited
similar enrichment for theC35E7.6mRNA, suggesting that
stable association of ADR-2 with C35E7.6 mRNA does
not require ADR-1 (Figure 4B). Interestingly, the C35E7.6
mRNA was previously shown to be bound by ADR-1 in
vivo, and binding of ADR-1 to C35E7.6 mRNA increased
in the absence of adr-2 (36), suggesting that ADR-1 and
ADR-2 may compete for binding to some mRNAs.
Examination of four known edited mRNAs using the
ADR-2 RIP assay suggests that ADR-1 promotes stable
binding of ADR-2 to a subset of mRNAs. To determine
whether this mechanism to promote ADR-2 mRNA bind-
ing is widespread in the transcriptome, the ADR-2 im-
munoprecipitates from WT and adr-1(-) lysates, as well
as the negative control immunoprecipitates from adr-2(-)
lysates, were subjected to high-throughput RNA sequenc-
ing (RIP-seq). In addition, high-throughput sequencing
was performed on RNA isolated from each worm strain
before immunoprecipitation, which serves as a normaliza-
tion for the transcript expression in the worm strains. To
identify RNAs that immunoprecipitated with ADR-2, dif-
ferential enrichment of transcripts in the WT immunopre-
cipitates (normalized to the transcripts present in the WT
worms) compared to the immunoprecipitates from adr-2(-)
worms (normalized to the transcripts present in the adr-2(-
) worms) was performed for two biological replicates using
DESeq2 (52). From this analysis, 1235 transcripts were sig-
nificantly enriched in the ADR-2 immunoprecipitates from
WT worms (Figure 4C and Supplementary Table S1). Im-
portantly, 62% of these transcripts have previously been re-
ported to contain editing sites, which is more than expected
by random chance (42%), suggesting these are in fact bona
fide ADR-2 target RNAs (Supplementary Table S1). To
determine whether ADR-1 was required for ADR-2 asso-
ciation with target RNAs, ADR-2 RIP-seq from adr-1(-)
worms was analyzed and identified 423 transcripts signifi-
cantly enriched in the ADR-2 immunoprecipitates (Figure
4C and Supplementary Table S2). When comparing these
423 transcripts to the 1235 ADR-2-associated RNAs iden-
tified fromWTworms, a majority (252) were common. The
lack of enrichment for the other 983 transcripts bound in
WT worms was not due to a lack of expression or differen-
tial expression of the transcripts between WT and adr-1(-)
worms (Supplementary Table S3). These data indicate that
ADR-1 is required for 80% of the transcripts to associate
with ADR-2 in WT worms. Interestingly, 171 transcripts
were enriched in the ADR-2 immunoprecipitates from adr-
1(-), but not WT worms, suggesting that in the absence of
adr-1, ADR-2may associate with some unique target RNAs
(Figure 4C).
To determine whether the ability of ADR-1 to di-
rect ADR-2 to specific transcripts correlates with func-
tional consequences on RNA, we performed de novo edit-
ing site identification and quantification using our re-
cently developed software, SAILOR (37) on the RNA-
sequencing (RNA-seq) datasets from the lysates before
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Figure 4. ADR-1 is required for ADR-2 to stably bind to a majority of mRNAs in vivo. (A) Lysates from the indicated worm strains were incubated with
magnetic beads, which were pre-incubated with ADR-2 antibodies. A portion of the lysates before incubation with beads and the immunoprecipitation
(IP) were subjected to immunoblotting for ADR-2. Actin was used as a loading control for lysates. (B) Immunoprecipitates from (A) were treated with
proteinase K to release bound RNA. RNA was extracted and reverse transcribed. Bar graph represents the fold enrichment of cDNA present in the
immunoprecipitates divided by the cDNA present in input lysates from the indicated worm strains and normalized to the same ratio in adr-2(-) worms.
Error bars represent SEM for three biological replicates. A one-way ordinary ANOVA test was performed. Single, double and triple asterisks indicate
significant changes where P< 0.05, P< 0.005 and P≤ 0.001, respectively. (C) Circle diagrams representing the 1235 ADR-2-bound targets identified from
ADR-2 RIP-seq in WT worms (red) and the 423 ADR-2-bound targets identified from ADR-2 RIP-seq in adr-1(-) worms (yellow), with targets identified
in both datasets represented by orange overlapping region. (D) Editing levels from the RNA-seq data for representative sites (see Supplementary Table S4
for all sites) in 21 transcripts that are bound to ADR-2 in WT worms, but not adr-1(-) worms.
ADR-2 immunoprecipitation described above. Although
these datasets are not sequenced to the depth needed to
identify all edited sites, from the WT RNA-seq, we iden-
tified 578 editing sites within the 1406 ADR-2-bound tran-
scripts (both circles in Figure 4C, data not shown). To de-
termine the impact of ADR-1 on editing, we quantified
editing at these sites in the input RNA-seq datasets from
the ADR-2 RIP experiment in adr-1(-) worms. Within 23
ADR-2-bound transcripts, 260 editing sites had significant
read coverage in the adr-1(-) RNA-seq to quantify editing
using SAILOR (Supplementary Table S4). Of these 23 tran-
scripts, 21 transcripts contain 189 sites that have decreased
editing (>5%) in adr-1(-) worms (Figure 4D and Supple-
mentary Table S4). Importantly, all 21 of these transcripts
exhibit ADR-1-dependent ADR-2 binding. Together, these
data indicate that ADR-1 directs the substrate specificity
of ADR-2 in vivo and increasing the association of ADR-2
with target RNAs is the mechanism by which ADR-1 pro-
motes editing.
DISCUSSION
In this study, we provide evidence that the C. elegans
ADAR enzyme, ADR-2, functions as a complex with the
deaminase-deficient ADAR family member, ADR-1. Using
both in vitro dsRNAbinding and transcriptome-wide exam-
ination ofADR-2 associationwith cellular RNAs, we found
that ADR-1 has>100-fold greater affinity for dsRNA com-
pared to ADR-2, and stable interaction of ADR-2 with
most target mRNAs in vivo requires ADR-1. Using WT
and mutant ADR-1 proteins expressed in the worm and
as recombinant proteins, we were able to demonstrate that
ADR-1 primarily uses the first dsRBD to bind mRNA in
vivo, despite being able to use each individual dsRBD to
bind to dsRNA in vitro (Figures 1 and 2). These data sug-
gest that studying ADAR binding to dsRNA in vitro is un-
likely to reveal specificity determinants, which is consistent
with recent data on another dsRBP, ILF3 (53). In addi-
tion, these data suggested that the second dsRBD of ADR-
1 might be performing a different role in vivo. Our co-IP
analysis from worms revealed that mutation of the second
dsRBD of ADR-1 abolished the interaction with ADR-2
without significantly affecting the ability of ADR-1 to in-
teract with mRNA (Figures 2 and 3). Together, these data
indicate that ADR-1 and ADR-2 physically interact inde-
pendent of RNA binding.
We propose a model in which ADR-1 and ADR-2 form
a heterodimer primarily via the second dsRBD of ADR-
1 and the dsRBD of ADR-2 (Graphical abstract). This
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heterodimeric complex binds cellular RNAs via the first
dsRBD of ADR-1, which promotes stable association of
ADR-2 with substrates to allow for efficient editing. Our
proposed molecular mechanism, in which a co-factor not
only recognizes, but also tethers an ADAR enzyme to
its substrate, has not been demonstrated in any other or-
ganism. Human and Drosophila ADAR-editing enzymes
have been reported to form dimers (30,51,54,55). However,
whether dimerization is required for editing activity (56)
and/or mediated by interactions with RNA (46) for ADAR
function in vivo is both controversial and unknown (57).
A particular complication in previous studies of dimeriza-
tion mediated by dsRBDs is that the KKxxK motif in the
dsRBD is classically defined as important for dsRNA bind-
ing and when mutated to EAxxA resulted in both disrup-
tion of the protein–protein interaction and altered in vitro
dsRNAbinding.However, our in vivo results clearly demon-
strate that mutation of the KKxxK motif in the second
dsRBD of ADR-1 does not significantly impact ADR-1
binding to mRNA but does disrupt the protein–protein in-
teraction with ADR-2 (Figures 2 and 3). To the best of our
knowledge, this is the first time that ADAR dsRBD mu-
tants have been studied for effects on in vivo binding to spe-
cific mRNAs. It will be interesting to expand this analysis
transcriptome-wide to determine if the second dsRBD of
ADR-1 contributes to recognition of specific RNAs or if
this domain is only used for protein–protein interactions.
The use of a co-factor to promote RNA binding of a
modification enzyme to substrates is widespread outside of
the ADAR family. For example, the human and fly RNA-
binding proteins, RBM15 and RBM15B, bind the RNA
methyltransferasemachinery and recruit it to transcripts for
methylation of specific adenosines (58,59). In addition, cy-
tidine to uridine editing of mRNA by the apolipoprotein
B mRNA editing catalytic polypeptide (APOBEC1) fam-
ily requires an RNA-binding co-factor, RBM47 (60). Our
data indicate that, similar to the function of mammalian
RBM47, C. elegans ADR-1 both physically interacts with
ADR-2 and promotes stable binding of the complex to
RNA to allow ADR-2 to properly edit. However, previous
studies have shown that ADR-1 is not required for ADR-2
to edit all adenosines (12,36,61) and our RIP studies iden-
tified 423 transcripts that associate with ADR-2 in the ab-
sence of ADR-1 (Supplementary Table S3). These data sug-
gest that the mode of substrate recognition by ADR-2 dif-
fers among various transcripts. However, the low appar-
ent affinity of ADR-2 for dsRNA raises the question of
whether or not ADR-2 is capable of using its dsRBD to
bind targets in vivo. The amino acid sequence alignment
of dsRBDs from ADAR family members indicates that the
ADR-2 dsRBD has a valine within the 1 helix instead of
a glutamate residue, which is known to be one of the two
dsRNA minor groove interaction sites for dsRBDs (62).
Mutation of this glutamate residue to alanine in the dsRBP,
Staufen, abolished dsRNA binding (45). Future studies to
examineADR-2 associationwith cellular RNAs in different
tissues and at different points in development will be criti-
cal to understanding the ability of ADR-2 to directly bind
transcripts and/or associate with RNA-binding co-factors
other than ADR-1. In our current in vitro studies, the bind-
ing ofADR-2 alone to dsRNAappeared to exhibit coopera-
tive binding (sharp transition from unbound to fully bound
dsRNA,Hill coefficient of∼4.4), suggesting the weak affin-
ity of ADR-2 might only be physiological relevant in cells
with high expression of ADR-2. In contrast, the higher
affinity to dsRNA for ADR-2 in complex with ADR-1 ex-
hibits less cooperative binding to dsRNA (Hill coefficient of
∼1.2), suggesting that the interaction of ADR-2withADR-
1 in order to bind substrates may be most important in cells
with low expression of ADR-2. Further in vitro studies of
the dynamics of ADR-2 interaction with different dsRNAs
may provide insight into how ADR-2 binds and edits cer-
tain transcripts in the absence of ADR-1.
Many types of DNA and RNA modifications are cat-
alyzed by a complex of two proteins, where one subunit
catalyzes the modification reaction and the partner sub-
unit is not enzymatically active (63–65). Our study is the
first to demonstrate such a complex for the ADAR fam-
ily of enzymes. However, the related adenosine deaminases
that act on tRNA (ADATs) function as a heterodimer,
where ADAT2 is the catalytic subunit and ADAT3 in-
creases ADAT2 binding to tRNAandmay contribute to the
zinc coordination required for adenosine deamination (66).
While our regulatory mechanism for the ability of ADR-1
to promote editing by ADR-2 involves a complex similar to
ADAT2/3, our data also suggest that ADR-2 has functions
that do not require, and may even compete with, ADR-1
mRNA binding. Therefore, unlike ADAT2, which requires
ADAT3 for A-to-I editing of tRNA, C. elegans ADR-2
is also able to function as an A-to-I editing enzyme inde-
pendent of complex formation with ADR-1. Future work
aimed at dissecting the cellular pathways that control dy-
namics of complex formation between ADR-1 and ADR-2
will be critical for understanding the differentmodes of sub-
strate recognition by ADAR enzymes.
In summary, our results indicate that both ADR-1 bind-
ing to mRNA and physical interactions between ADR-1
and ADR-2 underlie the regulatory mechanism by which
ADR-1 promotes ADR-2 editing of specific transcripts.
The conservation of editing-deficientADARproteins opens
the possibility that human ADAR-editing enzymes could
also interact with deaminase-deficient ADAR family mem-
bers, or other dsRBPs, to recognize specific target mR-
NAs in vivo. In this regard, it was recently reported that
binding of human ADAR2 to a specific transcript (CTN-
RNA) is enhanced by ADAR1 binding to the same tran-
script, and vice versa (67,68). The authors propose that
ADAR1 and ADAR2 interact in an RNA-dependent man-
ner as a reduction in both proteins is observed in the co-IP
treated with RNase (67). An alternative possibility is that
the two proteins physically associate to bind some tran-
scripts and co-localize to other transcripts (in an RNA-
dependentmanner), wherein treatment with nuclease would
show a reduction in the ability of the two proteins to co-
immunoprecipitate. In this regard, our previous co-IP study
of C. elegans ADR-1 and ADR-2 showed a reduction in
protein levels when the immunoprecipitates were treated
with RNase, but with a RNase-stable portion of both pro-
teins in the immunoprecipitate (36). However, in this study,
we were able to identify a mutant of ADR-1 that had simi-
lar mRNA binding as WT ADR-1 but exhibited a defect in
binding toADR-2, indicating the two proteins interact in an
9658 Nucleic Acids Research, 2018, Vol. 46, No. 18
RNA-independent manner. Future studies of mammalian
ADARs should examine how effects of RNA-binding mu-
tants of one ADAR family member impact the ability to co-
immunoprecipitate other ADAR family members and how
these RNA-binding mutants impact RNA binding to test
whether physical association between mammalian ADARs
contributes to recognition of specific substrates.
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